FDA grants orphan drug status to Inhibikase's IKT-001 for PAH

Inhibikase Therapeutics announced on July 23, 2026 that the FDA had granted Orphan Drug Designation to IKT-001, a prodrug of imatinib mesylate, for the treatment of Pulmonary Arterial Hypertension.¹ The designation was issued by the FDA's Office of Orphan Products Development.¹

The company noted that the FDA's orphan designation applies to the active moiety of IKT-001, imatinib, rather than a specific formulation.¹ Orphan status carries potential development incentives. As Inhibikase described it, the designation provides eligibility for tax credits on qualified clinical trial costs, exemption from certain FDA user fees, and the potential for seven years of market exclusivity upon regulatory approval.¹ Such designations are reserved for investigational therapies intended to treat rare diseases affecting fewer than 200,000 patients in the United States.¹

CEO Mark Iwicki said the designation reflects the high unmet medical need among the approximately 50,000 people suffering from PAH in the United States.¹ He also pointed to prior data, saying presentations of IKT-001 pre-clinical data at the American Thoracic Society International Conference in Orlando demonstrated improvements in pulmonary vascular and hemodynamic markers of PAH, together with a lower potential for GI toxicity compared to imatinib mesylate.¹

Inhibikase's imatinib-based candidate stems from a drug first approved in the United States in 2001 for various cancers and blood disorders, with more than 20 years of clinical use and a well-characterized safety profile, and the first reported use of imatinib in PAH occurring in 2005.¹ The company said its single pivotal Phase 3 clinical study in PAH, spanning approximately 180 sites around the world and named IMPROVE-PAH, is actively enrolling patients.¹